Combination therapy with leflunomide and genetic engineering biological agents
The paper gives data on the use of a combination of genetic engineering biological agents (GEBAs) and leflunomide in patients with rheumatoid arthritis (RA). In accordance with the international guidelines, the majority of GEBAs should be given in a combination with methotrexate (MTX), which increas...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2011-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/353 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The paper gives data on the use of a combination of genetic engineering biological agents (GEBAs) and leflunomide in patients with rheumatoid arthritis (RA). In accordance with the international guidelines, the majority of GEBAs should be given in a combination with methotrexate (MTX), which increases the efficacy of a number of GEBAs (tumor necrosis factor-α inhibitors, rituximab) and affects tolerability (remikeid, humira). However, MTX cannot be always used in real practice. The data given in the paper on the efficiency and safety of the coadministration of leflunomide and a GEBA in patients with active RA, which are based on the results of randomized studies and national registers, including the Russian one, point to the compatibility of the results of treatment with this and GEBA-MTX combinations. |
|---|---|
| ISSN: | 1996-7012 2310-158X |